Rayence Co

Rayence Co Debt Growth

The Year-over-Year Debt Growth of Rayence Co (228850.KQ) as of Oct 21, 2026 is 16.57 %. In the previous year, Year-over-Year Debt Growth was 19.47 % — a change of -14.87% (lower).

Debt Growth

16.57 %

YoY

-14.87%

Last updated:

Year-over-Year Debt Growth of Rayence Co is 2024 16.57 % . Year-over-Year Debt Growth of Rayence Co was 2023 19.47 % . It decreases by -14.87% lower compared to the previous year.

The Rayence Co Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2017
-22.08 KRW
Jan 1, 2018
-61.37 KRW
Jan 1, 2019
263.30 KRW
Jan 1, 2020
-0.75 KRW
Jan 1, 2021
-11.68 KRW
Jan 1, 2022
-47.85 KRW
Jan 1, 2023
19.47 KRW
Jan 1, 2024
16.57 KRW
The Rayence Co Debt Growth history
YEARDebt GrowthYoY
16.57 %-14.87%
19.47 %-140.68%
-47.85 %+309.66%
-11.68 %+1,460.37%
-0.75 %-100.28%
263.30 %-529.00%
-61.37 %+177.93%
-22.08 %-67.58%
-68.11 %+1,426.45%
-4.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Year-over-Year Debt Growth of Rayence Co is 16.57 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Rayence Co since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Rayence Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Rayence Co

All Key Metrics — Rayence Co